# Craig Mundie

> Craig Mundie is a seed investor in Seattle backing Life Science and Chemical. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Location: Seattle, United States
- Total investments: 4
- Last investment: Jan 2019
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/craig-mundie-a61691a5
- Website: https://x.com/MundieCraig
- Facebook: https://www.facebook.com/craigmu

Craig Mundie is a seed investor in Seattle focused on Life Science and Chemical. Craig J. Mundie is based out of Seattle, Washington, and is the Owner of Mundie & Associates LLC. Craig previously worked at Microsoft as a Chief Research and Strategy Officer. Craig J. Mundie attended the Georgia Institute of Technology.

## Contacts

5 contacts available for Craig Mundie: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/craig-mundie?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Life Science | 2 | 50% |
| Chemical | 1 | 25% |
| Genetics | 1 | 25% |
| Therapeutics | 1 | 25% |
| Biotechnology | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 25% |
| Series B | 1 | 25% |
| Series C | 1 | 25% |
| Funding Round | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Stoicheia | Stoicheia is a nanotechnology company accelerating materials discovery by defining and expanding the materials genome. Using its proprietary lithography technology, Stoicheia has developed a way to create Megalibraries of nanomaterials on a chip. The company's technology also can be used to combine elements in new ways — already creatingstructures comprising up to seven elements. | $5M | Seed | Jan 27, 2019 | https://www.stoicheia.ai |
| Exicure | Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $20M |  | Sep 27, 2017 | http://www.exicuretx.com/index.php |
| Exicure | Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $13.6M | Series C | Jun 17, 2014 | http://www.exicuretx.com/index.php |
| Exicure | Exicure is Formerly Known as AuraSense Therapeuticsis. Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets. Our 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. Our lead programs address diseases from inflammatorydisorders to oncology.SNA constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. SNA constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. Moreover, SNAs can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease. | $5.4M | Series B | Dec 21, 2011 | http://www.exicuretx.com/index.php |

4 of 4 investments shown.

## Co-investors
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 1 deal together
- [Kairos Ventures](https://shizune.co/investors/profile/kairos-venture-investments-llc) — VC Fund, 1 deal together
- [Katalyst Securities](https://shizune.co/investors/profile/katalyst-securities) — VC Fund, 1 deal together
- [Tempus](https://shizune.co/investors/profile/tempus-3) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## Featured in investor lists
- [Life Science Angel Investors](https://shizune.co/investors/life-science-angel-investors)

## FAQ

### What does Craig Mundie invest in?

Craig Mundie invests primarily in Life Science, Chemical and Genetics startups, most often at Seed and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Craig Mundie?

Public channels for Craig Mundie include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Craig Mundie last invest?

The most recent investment recorded for Craig Mundie closed in Jan 2019. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co